コンテンツへスキップ
Merck
  • Bacteriological characterization of a Mycobacterium parascrofulaceum strain isolated from a Chinese pneumonia patient.

Bacteriological characterization of a Mycobacterium parascrofulaceum strain isolated from a Chinese pneumonia patient.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2014-05-27)
Guan Liu, Gui-Rong Wang, Xia Yu, Qian Liang, Jing Mu, Yuan-Yuan Shang, Ying Ling, Hai-Qing Zhang, Su-Hua Zheng, Hai-Rong Huang
要旨

A Mycobacterium parascrofulaceum strain was isolated from a pneumonia patient-the first such reported case from China. The bacteriological characteristics of the strain were determined. Species identification was performed by homologue gene sequence comparison, then a series of biochemical tests was conducted to elucidate the bacteriological characteristics. Drug susceptibility and pathogenicity to mice of the strain were tested. The clinical M. parascrofulaceum strain presented a very similar phenotypic profile to that of Mycobacterium scrofulaceum. The M. parascrofulaceum strain was sensitive to rifabutin, rifapentine, clarithromycin, azithromycin, cefoxitin, and moxifloxacin in vitro. At week 2 post-infection, the lung tissues of mice demonstrated a local inflammatory response denoted by peri-bronchiolar inflammatory infiltrates. At weeks 4 and 8, the lung tissues showed peri-bronchiolar inflammatory infiltrates with large aggregates of lymphocytes and part of the tissue showed granulomatous lesions; there was no appreciable necrosis. The colony-forming units (CFU) count of infected lung and spleen increased gradually during the 8 weeks of the experiment. The M. parascrofulaceum strain isolated in China was sensitive to rifabutin, rifapentine, clarithromycin, azithromycin, cefoxitin, and moxifloxacin. The mycobacteria were capable of proliferating in mice and could lead to pathological changes in the lungs of the mice.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
レボフロキサシン, 98.0-102.0% anhydrous basis (HPLC)
Sigma-Aldrich
オフロキサシン, fluoroquinolone antibiotic
Sigma-Aldrich
アジスロマイシン
Sigma-Aldrich
4-アミノサリチル酸, 99%
Sigma-Aldrich
クラリトロマイシン, ≥95% (HPLC)
Supelco
スルファメトキサゾール
Supelco
イソニアジド, analytical standard, ≥99% (TLC)
USP
Levofloxacin, United States Pharmacopeia (USP) Reference Standard
USP
アジスロマイシン, United States Pharmacopeia (USP) Reference Standard
Supelco
スルファメトキサゾール, Pharmaceutical Secondary Standard; Certified Reference Material
USP
メロペネム, United States Pharmacopeia (USP) Reference Standard
Supelco
クラリトロマイシン, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
エチオナミド
Sigma-Aldrich
Rifapentine
USP
Amikacin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
クラリトロマイシン, 96.0-102.0% (HPLC)
USP
オフロキサシン, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
リファブチン, >98% (HPLC), powder
Supelco
オフロキサシン, Pharmaceutical Secondary Standard; Certified Reference Material
USP
スルファメトキサゾール, United States Pharmacopeia (USP) Reference Standard
Supelco
スルファメトキサゾール, VETRANAL®, analytical standard
USP
クラリトロマイシン, United States Pharmacopeia (USP) Reference Standard
Supelco
レボフロキサシン, analytical standard
USP
クラリトロマイシン, United States Pharmacopeia (USP) Reference Standard
アジスロマイシン 二水和物, European Pharmacopoeia (EP) Reference Standard
スルファメトキサゾール, European Pharmacopoeia (EP) Reference Standard
USP
アジスロマイシン, United States Pharmacopeia (USP) Reference Standard
システム適合性用アジスロマイシン, European Pharmacopoeia (EP) Reference Standard
USP
リファブチン, United States Pharmacopeia (USP) Reference Standard
アジスロマイシン 二水和物, European Pharmacopoeia (EP) Reference Standard